Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
NCT ID: NCT04281576
Last Updated: 2024-11-14
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
28 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-12-19
Study Completion Date
2024-06-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study is a prospective, single arm, phase II trial aimed to evaluate the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with XELOX for the treatment of unresectable, locally advanced or metastatic Gastroesophageal Junction (GEJ) or Gastric (GC) Adenocarcinoma who were previously untreated with systemic therapy. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
NCT04661150
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
ACTIVE_NOT_RECRUITING
PHASE2
A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer
NCT01364493
Gastric Cancer
COMPLETED
PHASE2
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
NCT04933227
Stomach Neoplasms
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
TERMINATED
PHASE2
Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma
NCT00816543
Gastric Cancer
COMPLETED
PHASE2
Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer
NCT03137004
Advanced Gastric Cancer
UNKNOWN
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PAST PRE-CLINICAL AND CLINICAL EXPERIENCE:
The effect of the electric fields (TTFields, TTF) has demonstrated significant activity in in vitro gastric cancer pre-clinical models both as a single modality treatment and in combination with chemotherapies. In addition, TTFields have shown to inhibit metastatic spread of malignant melanoma in in vivo experiment.
Prospective, multi-center clinical studies of TTFields have shown the safety of the treatment when administered to the abdomen for pancreatic cancer and ovarian cancer.
In addition, a phase III trial of Optune® (200 kHz) as monotherapy compared to active chemotherapy in recurrent glioblastoma patients showed TTFields to be equivalent to active chemotherapy in extending survival, associated with minimal toxicity, good quality of life, and activity within the brain (14% response rate). Finally, a phase III trial of Optune® combined with maintenance temozolomide compared to maintenance temozolomide alone has shown that combined therapy led to a significant improvement in both progression free survival and overall survival in patients with newly diagnosed glioblastoma without the addition of high grade toxicity and without decline in quality of life.
DESCRIPTION OF THE TRIAL:
All patients included in this trial are patients with unresectable Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma. In addition, all patients must meet all eligibility criteria.
All eligible patients will receive continuous Tumor Treating Fields (TTFields) - NovoTTF-100L (P) treatment at 150 KHz frequency, and XELOX regimen (combination of oxaliplatin + capecitabine). Patients will be assessed once every 9 weeks according to RECIST v1.1. Study treatment should be continued until disease progression, intolerable toxicity or withdrawal of informed consent.
The effect of the electric fields (TTFields, TTF) has demonstrated significant activity in in vitro gastric cancer pre-clinical models both as a single modality treatment and in combination with chemotherapies. In addition, TTFields have shown to inhibit metastatic spread of malignant melanoma in in vivo experiment.
Prospective, multi-center clinical studies of TTFields have shown the safety of the treatment when administered to the abdomen for pancreatic cancer and ovarian cancer.
In addition, a phase III trial of Optune® (200 kHz) as monotherapy compared to active chemotherapy in recurrent glioblastoma patients showed TTFields to be equivalent to active chemotherapy in extending survival, associated with minimal toxicity, good quality of life, and activity within the brain (14% response rate). Finally, a phase III trial of Optune® combined with maintenance temozolomide compared to maintenance temozolomide alone has shown that combined therapy led to a significant improvement in both progression free survival and overall survival in patients with newly diagnosed glioblastoma without the addition of high grade toxicity and without decline in quality of life.
DESCRIPTION OF THE TRIAL:
All patients included in this trial are patients with unresectable Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma. In addition, all patients must meet all eligibility criteria.
All eligible patients will receive continuous Tumor Treating Fields (TTFields) - NovoTTF-100L (P) treatment at 150 KHz frequency, and XELOX regimen (combination of oxaliplatin + capecitabine). Patients will be assessed once every 9 weeks according to RECIST v1.1. Study treatment should be continued until disease progression, intolerable toxicity or withdrawal of informed consent.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Gastric Cancer
GastroEsophageal Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NovoTTF-100L(P)
Patients receive TTFields using the NovoTTF-100L(P) System together with XELOX. For HER-2 positive patients, Trastuzumab is given together with XELOX.
Group Type
EXPERIMENTAL
NovoTTF-100L(P)
Intervention Type
DEVICE
Patients receive continuous TTFields treatment using the NovoTTF-100L(P) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
Oxaliplatin
Intervention Type
DRUG
Oxaliplatin 130 mg/m\^2 intravenous infusion will be administered once every 3 weeks
Capecitabine
Intervention Type
DRUG
Capecitabine 1000mg/m\^2 taken by mouth, twice daily on day 1-14, 3 weeks per cycle
Trastuzumab
Intervention Type
DRUG
Trastuzumab (HER-2 positive patients only) intravenous infusion will be administered once every 3 weeks on Day 1 of each cycle. First dose is 8mg/kg, followed by 6 mg/kg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NovoTTF-100L(P)
Patients receive continuous TTFields treatment using the NovoTTF-100L(P) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
Intervention Type
DEVICE
Oxaliplatin
Oxaliplatin 130 mg/m\^2 intravenous infusion will be administered once every 3 weeks
Intervention Type
DRUG
Capecitabine
Capecitabine 1000mg/m\^2 taken by mouth, twice daily on day 1-14, 3 weeks per cycle
Intervention Type
DRUG
Trastuzumab
Trastuzumab (HER-2 positive patients only) intravenous infusion will be administered once every 3 weeks on Day 1 of each cycle. First dose is 8mg/kg, followed by 6 mg/kg.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
TTFields
Eloxatin
Xeloda
Herceptin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Willing to and be able to sign an informed consent form
2. Male or female aged ≥ 18 years
3. Be able to receive the treatment in compliance with the study protocol in the discretion of the investigator
4. ECOG Performance status score 0 or 1
5. Histologically confirmed unresectable, locally advanced or metastatic Gastroesophageal Junction (GEJ) or Gastric (GC) Adenocarcinoma. The subject must be previously untreated with systemic treatment (including chemotherapy, targeted therapy, and Onco-Immunotherapy), and without resection of primary gastric focus.
6. Subjects must have at least one measurable lesion as per RECIST 1.1 criteria; and the tumor assessment baseline should be performed and established by the investigator within 28 days prior to study treatment.
7. Life expectancy ≥ 3 months
8. The allowed previous treatment: Palliative radiotherapy for bone metastasis is allowed if it has been completed within 2 weeks prior to the study treatment and all treatment-related toxicity should be recovered to Grade 1 before enrollment, according to CTCAE 5.0.
9. Women of childbearing potential must have a negative serum pregnancy test result during screening. Post-menopausal women and surgically sterilized women are not required to undergo a pregnancy test. Females of childbearing potential/males and its partners who are sexually active must agree to adopt methods of contraception from signing the ICFs to within at least 6 months after the last dose of study drug. Besides, male subjects must be willing to refrain from sperm donation during this time.
10. Able to operate the NovoTTF-100L (P) System independently or with the help of a caregiver.
2. Male or female aged ≥ 18 years
3. Be able to receive the treatment in compliance with the study protocol in the discretion of the investigator
4. ECOG Performance status score 0 or 1
5. Histologically confirmed unresectable, locally advanced or metastatic Gastroesophageal Junction (GEJ) or Gastric (GC) Adenocarcinoma. The subject must be previously untreated with systemic treatment (including chemotherapy, targeted therapy, and Onco-Immunotherapy), and without resection of primary gastric focus.
6. Subjects must have at least one measurable lesion as per RECIST 1.1 criteria; and the tumor assessment baseline should be performed and established by the investigator within 28 days prior to study treatment.
7. Life expectancy ≥ 3 months
8. The allowed previous treatment: Palliative radiotherapy for bone metastasis is allowed if it has been completed within 2 weeks prior to the study treatment and all treatment-related toxicity should be recovered to Grade 1 before enrollment, according to CTCAE 5.0.
9. Women of childbearing potential must have a negative serum pregnancy test result during screening. Post-menopausal women and surgically sterilized women are not required to undergo a pregnancy test. Females of childbearing potential/males and its partners who are sexually active must agree to adopt methods of contraception from signing the ICFs to within at least 6 months after the last dose of study drug. Besides, male subjects must be willing to refrain from sperm donation during this time.
10. Able to operate the NovoTTF-100L (P) System independently or with the help of a caregiver.
Exclusion Criteria
1. White blood cell count (WBC) \< 2 × 10\^9 / L
2. Absolute neutrophil count (ANC) \< 1.5 × 10\^9 / L
3. Platelet count \< 100 × 10\^9 / L
4. Hemoglobin \< 90 g/L
5. Serum albumin \< 30 g/L
6. Serum creatinine \> 1.5 × ULN, or creatinine clearance\< 60 mL/min/1.73 m\^2 calculated by Cockcroft-Gault
7. Serum total bilirubin \> 1.5 × ULN
8. AST, ALT, ALP:
1. Patients without liver metastasis or bone metastases i. AST or ALT \>1.5 × ULN and ALP \> 2.5 × ULN ii. AST or ALT \>2.5 × ULN
2. Patients with liver metastasis and without bone metastases i. AST or ALT \> 5 × ULN and ALP \> 2.5 × ULN
3. Patients with liver metastasis and bone metastases i. AST or ALT \> 5 × ULN and ALP \> 10 × ULN
4. Patients without liver metastasis and with bone metastases i. AST or ALT \> 1.5 × ULN and ALP \> 10 × ULN
9. Coagulation function: International Normalized Ratio (INR) \> 2.3 or Prothrombin Time (PT) of \> 6 seconds above the reference.
10. The other abnormal laboratory test:
1. Electrolyte disorder including hyponatremia, hypokalemia and hypophosphatemia before the first dose, which cannot be restored by fluid and electrolyte therapies;
2. HIV positive;
11. Metastases to central nervous system with clinical symptoms. Patients who previously received treatments for the metastases to central nervous system, are stable and meet the following requirements are allowed to be enrolled:
1. No treatment for the metastases to central nervous system during the screening period (e. g. surgery, radiotherapy, corticosteroid therapy-prednisolone \> 10 mg/day or equivalent)
2. No progress in central nervous system lesions as indicated by MRI or CT within 14 days prior to the study treatment
3. No meningeal metastasis or spinal cord compression
12. Moderate or severe ascites defined by physical examination and/or CT confirmed
13. Non-healing wound or ulcer within 3 months prior to study enrollment, or history of bone fracture
14. Previous allogeneic organ transplantation or allogeneic bone marrow transplantation
15. Implantable electronic medical devices in the torso.
16. Peripheral neuropathy ≥ Grade 2 (CTCAE 5.0)
17. Except hearing loss, alopecia and fatigue, all toxic reactions caused by previous anti-tumor therapy \> Grade 1 (CTCAE 5.0)
18. Other malignant tumors have occurred over the past five years, with the exception of locally curable cancers treated with radical therapy, such as basal or squamous cell skin cancer, superficial bladder cancer, or in situ carcinoma of the cervix, prostate or breast.
19. Subjects who are at increased risk of bleeding or thrombosis:
1. Clinically significant bleeding within 3 months prior to screening or clear bleeding tendency;
2. Gastrointestinal hemorrhage within 3 months prior to screening or clear tendency of gastrointestinal hemorrhage;
3. Arterial/venous thromboembolic events within 6 months prior to screening, such as cerebrovascular accident (including transient ischemic attack), pulmonary embolism, etc.;
4. Require anticoagulation therapy with an agent such as warfarin or heparin;
5. Require chronic anti-platelet therapy (such as aspirin≥100 mg/day, clopidogrel, etc.);
20. History of cardiovascular disease:
1. NYHA (New York Heart Association) grade 3 and 4 congestive heart failure;
2. Unstable angina pectoris or newly diagnosed angina pectoris or myocardial infarction within 12 months prior to screening;
3. Arrhythmias requiring medications other than β-blockers;
4. Patients with valvular heart disease of ≥ CTCAE grade 2;
5. Hypertension inadequately controlled by drugs (systolic pressure \>150 mmHg or diastolic pressure \>90 mmHg);
21. The investigator considers that there may be an increased risk related to the study or study treatment, or any serious or uncontrolled systemic diseases, such as infection, diabetes, hypertension, that affect the patient's ability to receive the study treatment.
22. Treatment with systemic anticancer agents (including but not limited to chemotherapy, targeted therapy, onco-immunotherapy, and biotherapy (tumor vaccines, cytokines, or cancer related growth factors)) 14 days before the study treatment, or traditional Chinese herbal medicine or Chinese patent medicine for anti-tumor therapy 7 days prior to the treatment.
23. Patients with active chronic hepatitis B or hepatitis C, or co-infection of both, patients with hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) positive during screening who have hepatitis B virus (HBV) DNA titer \> 500 IU/ mL and HCV RNA detectable can be enrolled after active hepatitis B or hepatitis C infection that requires treatment have been ruled out. During the study treatment, corresponding anti-viral treatment should be given.
24. Known history of allergies or hypersensitivities to medical adhesives, hydrogel, standard drugs used in this study or their components.
25. Known history of alcohol or drug abuse.
26. Females who are pregnant or breastfeeding.
2. Absolute neutrophil count (ANC) \< 1.5 × 10\^9 / L
3. Platelet count \< 100 × 10\^9 / L
4. Hemoglobin \< 90 g/L
5. Serum albumin \< 30 g/L
6. Serum creatinine \> 1.5 × ULN, or creatinine clearance\< 60 mL/min/1.73 m\^2 calculated by Cockcroft-Gault
7. Serum total bilirubin \> 1.5 × ULN
8. AST, ALT, ALP:
1. Patients without liver metastasis or bone metastases i. AST or ALT \>1.5 × ULN and ALP \> 2.5 × ULN ii. AST or ALT \>2.5 × ULN
2. Patients with liver metastasis and without bone metastases i. AST or ALT \> 5 × ULN and ALP \> 2.5 × ULN
3. Patients with liver metastasis and bone metastases i. AST or ALT \> 5 × ULN and ALP \> 10 × ULN
4. Patients without liver metastasis and with bone metastases i. AST or ALT \> 1.5 × ULN and ALP \> 10 × ULN
9. Coagulation function: International Normalized Ratio (INR) \> 2.3 or Prothrombin Time (PT) of \> 6 seconds above the reference.
10. The other abnormal laboratory test:
1. Electrolyte disorder including hyponatremia, hypokalemia and hypophosphatemia before the first dose, which cannot be restored by fluid and electrolyte therapies;
2. HIV positive;
11. Metastases to central nervous system with clinical symptoms. Patients who previously received treatments for the metastases to central nervous system, are stable and meet the following requirements are allowed to be enrolled:
1. No treatment for the metastases to central nervous system during the screening period (e. g. surgery, radiotherapy, corticosteroid therapy-prednisolone \> 10 mg/day or equivalent)
2. No progress in central nervous system lesions as indicated by MRI or CT within 14 days prior to the study treatment
3. No meningeal metastasis or spinal cord compression
12. Moderate or severe ascites defined by physical examination and/or CT confirmed
13. Non-healing wound or ulcer within 3 months prior to study enrollment, or history of bone fracture
14. Previous allogeneic organ transplantation or allogeneic bone marrow transplantation
15. Implantable electronic medical devices in the torso.
16. Peripheral neuropathy ≥ Grade 2 (CTCAE 5.0)
17. Except hearing loss, alopecia and fatigue, all toxic reactions caused by previous anti-tumor therapy \> Grade 1 (CTCAE 5.0)
18. Other malignant tumors have occurred over the past five years, with the exception of locally curable cancers treated with radical therapy, such as basal or squamous cell skin cancer, superficial bladder cancer, or in situ carcinoma of the cervix, prostate or breast.
19. Subjects who are at increased risk of bleeding or thrombosis:
1. Clinically significant bleeding within 3 months prior to screening or clear bleeding tendency;
2. Gastrointestinal hemorrhage within 3 months prior to screening or clear tendency of gastrointestinal hemorrhage;
3. Arterial/venous thromboembolic events within 6 months prior to screening, such as cerebrovascular accident (including transient ischemic attack), pulmonary embolism, etc.;
4. Require anticoagulation therapy with an agent such as warfarin or heparin;
5. Require chronic anti-platelet therapy (such as aspirin≥100 mg/day, clopidogrel, etc.);
20. History of cardiovascular disease:
1. NYHA (New York Heart Association) grade 3 and 4 congestive heart failure;
2. Unstable angina pectoris or newly diagnosed angina pectoris or myocardial infarction within 12 months prior to screening;
3. Arrhythmias requiring medications other than β-blockers;
4. Patients with valvular heart disease of ≥ CTCAE grade 2;
5. Hypertension inadequately controlled by drugs (systolic pressure \>150 mmHg or diastolic pressure \>90 mmHg);
21. The investigator considers that there may be an increased risk related to the study or study treatment, or any serious or uncontrolled systemic diseases, such as infection, diabetes, hypertension, that affect the patient's ability to receive the study treatment.
22. Treatment with systemic anticancer agents (including but not limited to chemotherapy, targeted therapy, onco-immunotherapy, and biotherapy (tumor vaccines, cytokines, or cancer related growth factors)) 14 days before the study treatment, or traditional Chinese herbal medicine or Chinese patent medicine for anti-tumor therapy 7 days prior to the treatment.
23. Patients with active chronic hepatitis B or hepatitis C, or co-infection of both, patients with hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) positive during screening who have hepatitis B virus (HBV) DNA titer \> 500 IU/ mL and HCV RNA detectable can be enrolled after active hepatitis B or hepatitis C infection that requires treatment have been ruled out. During the study treatment, corresponding anti-viral treatment should be given.
24. Known history of allergies or hypersensitivities to medical adhesives, hydrogel, standard drugs used in this study or their components.
25. Known history of alcohol or drug abuse.
26. Females who are pregnant or breastfeeding.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zai Lab (Shanghai) Co., Ltd.
INDUSTRY
Sponsor Role
collaborator
NovoCure Ltd.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Queen Mary Hospital
Hong Kong, , Hong Kong
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Hong Kong
References
Explore related publications, articles, or registry entries linked to this study.
Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95. doi: 10.1158/0008-5472.can-04-0083.
Reference Type
BACKGROUND
Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. doi: 10.1073/pnas.0702916104. Epub 2007 Jun 5.
Reference Type
BACKGROUND
Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbaly V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18.
Reference Type
BACKGROUND
Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, Wasserman Y, Ryffel B, Goldsher D, Palti Y. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009;26(7):633-40. doi: 10.1007/s10585-009-9262-y. Epub 2009 Apr 23.
Reference Type
BACKGROUND
Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, Cahal S, Shteingauz A, Chaudhry A, Kirson ED, Weinberg U, Palti Y. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Sci Rep. 2015 Dec 11;5:18046. doi: 10.1038/srep18046.
Reference Type
BACKGROUND
Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.
Reference Type
BACKGROUND
Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718.
Reference Type
BACKGROUND
Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018 Apr 1;4(4):495-504. doi: 10.1001/jamaoncol.2017.5082.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EF-31 / ZL-8301-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy
NCT05447234
NOT_YET_RECRUITING
EARLY_PHASE1
Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer
NCT02623153
UNKNOWN
PHASE2
Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
NCT04744649
UNKNOWN
PHASE2
Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
NCT07315854
RECRUITING
PHASE2
Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer
NCT01815853
COMPLETED
PHASE3
Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC
NCT06238167
NOT_YET_RECRUITING
PHASE2
Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients
NCT01618474
UNKNOWN
PHASE2
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
NCT06121700
RECRUITING
PHASE2
Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer
NCT04135781
UNKNOWN
PHASE3
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX
NCT01396707
COMPLETED
PHASE2
A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer
NCT01748773
COMPLETED
PHASE2
XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)
NCT01748851
TERMINATED
PHASE3
Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
NCT00525785
COMPLETED
PHASE2
SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
NCT06266871
NOT_YET_RECRUITING
PHASE1/PHASE2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05702229
RECRUITING
PHASE2
The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer
NCT02038621
UNKNOWN
PHASE2
Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma
NCT03083613
COMPLETED
PHASE2
XELOX With Capecitabine Maintenance or XELOX in Elderly Metastatic Adenocarcinoma of Stomach
NCT01798251
UNKNOWN
PHASE2
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
NCT01095120
UNKNOWN
PHASE2
Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer
NCT02289547
UNKNOWN
PHASE3
Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma
NCT05507658
COMPLETED
PHASE2
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
NCT06684158
NOT_YET_RECRUITING
PHASE2
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
NCT04908813
ACTIVE_NOT_RECRUITING
PHASE2
Preoperative Stomach Cancer Induction Chemotherapy and Radiation Therapy
NCT03223740
UNKNOWN
PHASE3